setmelanotide vs semaglutide Among participants 4 to 66 years of age with acquired hypothalamic obesity, setmelanotide, a melanocortin-4 receptor agonist, led to significantly greater reductions in body-mass index and hunger than placebo at 52 weeks Setmelanotide - an overview |

Tirzepatide typically starts at 2.5 mg weekly for 4 weeks and increases every 4 weeks (2.5 mg increments) toward 10-15 mg

The session used the earliest available published data for CT-388 (24-week interim from ADA/ENDO 2024) and projected a 48-week plateau of 24 to 26% based on trajectory extrapolation from tirzepatide's weight-loss kinetics

Table 1 summarises the baseline characteristics of individuals and baseline demographics of the whole network are summarised in ESM Results

Bubp J, Jen M, Matuszewski K (2015) Caring for Glucose-6-Phosphate Dehydrogenase (G6PD)Deficient Patients: Implications for Pharmacy

DKA, Diabetic ketoacidosis

Long-term data determines whether those results matter